- Home
- MYTE vs OGEN Comparison
MYTE vs OGEN Comparison
Compare MYTE & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYTE
- OGEN
- Stock Information
- Founded
- MYTE 2006
- OGEN 1996
- Country
- MYTE Germany
- OGEN United States
- Employees
- MYTE N/A
- OGEN N/A
- Industry
- MYTE Catalog/Specialty Distribution
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MYTE Consumer Discretionary
- OGEN Health Care
- Exchange
- MYTE Nasdaq
- OGEN Nasdaq
- Market Cap
- MYTE N/A
- OGEN 4.6M
- IPO Year
- MYTE 2021
- OGEN N/A
- Fundamental
- Price
- MYTE $7.71
- OGEN $0.20
- Analyst Decision
- MYTE Hold
- OGEN
- Analyst Count
- MYTE 1
- OGEN 0
- Target Price
- MYTE $5.00
- OGEN N/A
- AVG Volume (30 Days)
- MYTE 209.9K
- OGEN 340.9K
- Earning Date
- MYTE 05-14-2025
- OGEN 05-14-2025
- Dividend Yield
- MYTE N/A
- OGEN N/A
- EPS Growth
- MYTE N/A
- OGEN N/A
- EPS
- MYTE N/A
- OGEN N/A
- Revenue
- MYTE $912,559,271.00
- OGEN N/A
- Revenue This Year
- MYTE $11.96
- OGEN N/A
- Revenue Next Year
- MYTE $10.37
- OGEN N/A
- P/E Ratio
- MYTE N/A
- OGEN N/A
- Revenue Growth
- MYTE 12.41
- OGEN N/A
- 52 Week Low
- MYTE $3.18
- OGEN $0.19
- 52 Week High
- MYTE $12.50
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- MYTE 33.90
- OGEN 25.67
- Support Level
- MYTE $7.13
- OGEN $0.19
- Resistance Level
- MYTE $7.80
- OGEN $0.22
- Average True Range (ATR)
- MYTE 0.40
- OGEN 0.02
- MACD
- MYTE -0.03
- OGEN -0.01
- Stochastic Oscillator
- MYTE 29.13
- OGEN 9.00
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.